Use as an aid in the diagnosis of urothelial carcinoma in conjunction with standard diagnostic procedures and monitoring tumor recurrence.
Quantitative Enzyme Immunoassay
This test is New York DOH approved.
This test is intended as an aid in the management of patients with transitional cell carcinoma of the urinary tract (TCC/UT), and is used after surgical treatment to identify patients with residual or rapidly recurring TCC/UT. Values obtained with different test methods should not be used interchangeably. ARUP uses the Alere NMP22 Test Kit, an enzyme immunoassay (EIA) method.